The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2022 | Immune reconstitution after quadruplet therapy, autoSCT and MRD-adapted treatment cessation in NDMM
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, shares some insights into the findings of a correlative analysis on humoral immune reconstitution after quadruplet therapy, autologous transplantation, and measurable residual disease (MRD)-adapted treatment cessation in patients with newly diagnosed multiple myeloma (NDMM). This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
